These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2005-004502-82 A Phase II Study of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma 2015-12-22 due-trials
Reported results 2005-005707-42 A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury 2011-12-27 due-trials
Listed as ongoing, but also has a completion date 2006-006981-40 Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension? 2010-05-26 bad-data
Ongoing 2006-007018-39 Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve not-yet-due
Reported results 2007-001039-72 Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial 2016-11-28 due-trials
Ongoing 2007-006761-32 Vulval intraepithelial neoplasia: immune responses to human papillpmavirus. not-yet-due
Reported results Terminated 2008-000051-10 11C metomidate PET scanning for Conn's syndrome 2011-05-23 due-trials
Not reported 2008-007149-30 Optimal Treatment of Drug Resistant Hypertension 2015-06-26 due-trials
Not reported 2009-010068-41 Comparison of single and combination diuretics in low-renin hypertension 2015-06-26 due-trials
Reported results 2009-012776-27 The effect of sitagliptin on myocardial performance in patients with type 2 diabetes and coronary artery disease. 2013-03-20 due-trials
Reported results 2009-018119-14 Huntington's Disease Rilmenidine Safety Trial 2015-06-30 due-trials
Reported results Terminated 2010-021613-23 HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy 2014-09-25 due-trials
Reported results Terminated 2010-024624-20 A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT 2015-05-20 due-trials
Reported results 2011-003933-32 A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain 2012-01-31 due-trials
Reported results 2011-004936-75 An Evaluation of Losmapimod in patients with Chronic Obstructive Pulmonary Disease (COPD) with systemic inflammation stratified using fibrinogen (EVOLUTION) 2014-08-06 due-trials
Reported results 2011-005606-30 Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY 2017-08-08 due-trials
Reported results 2012-005570-56 Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) - a randomised controlled trial to establish the effectiveness and cost-effectiveness of metformin in preventing cardiovascular events ove... 2016-11-05 due-trials
Reported results Terminated 2012-005627-32 A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study 2016-03-28 due-trials
Reported results Terminated 2013-004200-19 Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) - A single-centre phase 2a study of Gemcitabine plus Nab-paclitaxel for borderline unresectable locally advanced pancreatic c... 2017-10-26 due-trials
Exempt 2014-000117-31 To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment in ... not-yet-due
Reported results 2014-000484-41 A Non-Randomised, Open Label, Pilot Trial of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA Related Overgrowth 2017-05-05 due-trials
Ongoing 2014-003145-99 A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already o... not-yet-due
Ongoing 2014-004948-35 A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic chronic subdural haematoma. not-yet-due
Ongoing 2015-002811-13 Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA not-yet-due
Ongoing 2015-005003-88 Survival Improvement with Cholecalciferol in Patients on Dialysis – The SIMPLIFIED Registry Trial not-yet-due
Ongoing 2016-000118-31 A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2) not-yet-due
Ongoing 2016-000165-23 ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM) not-yet-due
Ongoing 2016-003752-79 Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast can... not-yet-due
Ongoing 2017-001700-29 Targeted drug intervention to inhibit cancer progression in men on active surveillance for prostate cancer. Therapeutics in Active Prostate cancer Surveillance (TAPS01) not-yet-due
Ongoing 2017-003563-36 ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV) not-yet-due